Chemotherapy News and Research

Latest Chemotherapy News and Research

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.

22 Oct 2013

Pancreatic cancer patients may benefit from antibody-drug conjugates

Patients with pancreatic cancer may benefit from an investigational member of an emerging class of anticancer drugs called antibody-drug conjugates, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

22 Oct 2013

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

21 Oct 2013

Cell Therapeutics presents preclinical study results of PIXUVRI at AACR-NCI-EORTC meeting

Cell Therapeutics, Inc. (CTI) today announced the presentation of findings from a preclinical study of PIXUVRI® (pixantrone) that suggest its mechanism of inducing tumor cell death is novel and distinct from that of anthracyclines such as doxorubicin.

21 Oct 2013

Study: Skin tanning gene linked to higher risk for testicular cancer in white men

A gene important in skin tanning has been linked to higher risk for testicular cancer in white men, according to a study led by scientists from the U.S. National Institutes of Health and the University of Oxford in England.

19 Oct 2013

New prognostic tool forecasts survival of patients with advanced prostate cancer

For men with advanced prostate cancer that has progressed after taking hormones and undergoing chemotherapy, getting an accurate prognosis is critical to determine the next steps for treatment.

19 Oct 2013

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

ARIAD Pharmaceuticals, Inc. today announced that it is discontinuing the Phase 3 EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) trial of Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid leukemia.

18 Oct 2013

Combination of heat, doxorubicin drug and nanotech system may improve ovarian cancer treatment

The combination of heat, chemotherapeutic drugs and an innovative delivery system based on nanotechnology may significantly improve the treatment of ovarian cancer while reducing side effects from toxic drugs, researchers at Oregon State University report in a new study.

18 Oct 2013

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

Boehringer Ingelheim announced the submission of a Marketing Authorisation Application to the European Medicines Agency for the approval of its oral triple angiokinase inhibitor nintedanib, in combination with docetaxel, for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.

17 Oct 2013

Researchers find novel drug target for anaplastic thyroid carcinomas

Anaplastic thyroid carcinomas are aggressive tumors that do not respond to traditional radio- or chemotherapeutic agents, and there currently is no cure or effective treatment available. Median survival from diagnosis is 5 months, and although ATC accounts for only 1.7% of all thyroid cancers in the U.S., it is responsible for a large proportion of thyroid cancer-related deaths.

17 Oct 2013

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation , today announced the results of the MPACT phase III clinical trial of ABRAXANE® in combination with gemcitabine were published online in the October 16th edition of the New England Journal of Medicine.

17 Oct 2013

Light pulses stimulate designer peptides to trigger death pathway in cancerous cells

Researchers at Cardiff University have created a peptide (a small piece of protein), linked to a light-responsive dye, capable of switching 'on' death pathways in cancer cells. The peptide remains inactive until exposed to external light pulses which convert it into a cell death signal.

17 Oct 2013

New $1.9M research grant to support investigators to detect tumors in earliest stages of formation

The National Cancer Institute's new Provocative Questions research funding program has awarded a prestigious grant to researchers at the Case Comprehensive Cancer Center and Case Western Reserve University's Schools of Medicine and Engineering to study tumor detection at the earliest stages of growth.

16 Oct 2013

Acacia Pharma reports positive results from APD515 Phase II study for treatment of xerostomia

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces positive results from its Phase II study of APD515 for the treatment of xerostomia (dry mouth) in advanced cancer patients.

15 Oct 2013

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Crown Bioscience, Inc., a leading global drug discovery and development service company, today announces that it has entered into a collaboration with Xstrahl Ltd, a leading designer and manufacturer of X-Ray solutions for radiation biology research.

From Xstrahl 15 Oct 2013

Promising new type of cancer treatment to benefit more patients

More patients than ever stand to benefit from a promising new type of cancer treatment, after scientists compiled a library of molecules that can prime patients’ immune systems to fight a range of cancers including leukaemia, myeloma, lung cancer and skin cancer.

15 Oct 2013

Results announced for Phase II PRECEDENT trial of vintafolide for treatment of platinum-resistant ovarian cancer

Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte, Inc. (NASDAQ: ECYT) today announced the online publication of results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145), an investigational folate small molecule drug conjugate (SMDC), in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology.

15 Oct 2013

NICE issues second draft guidance on PIXUVRI for treatment of aggressive B-cell NHL

Cell Therapeutics, Inc. today announced that the National Institute for Health and Care Excellence, a non-departmental public body of the Department of Health in the United Kingdom, issued second draft guidance on PIXUVRI (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.

15 Oct 2013

Football-shaped artificial particles teach immune cells to recognize, destroy cancer cells

Researchers at Johns Hopkins have succeeded in making flattened, football-shaped artificial particles that impersonate immune cells. These football-shaped particles seem to be better than the typical basketball-shaped particles at teaching immune cells to recognize and destroy cancer cells in mice.

14 Oct 2013

PARP inhibitor drugs and chemotherapy can help women with ovarian cancer live longer

Conventional chemotherapy could further extend life in some women with ovarian cancer when used in tandem with a new type of targeted treatment, a new international study shows.

13 Oct 2013

Chemotherapy News and Research

Latest Chemotherapy News and Research

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

Pancreatic cancer patients may benefit from antibody-drug conjugates

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Cell Therapeutics presents preclinical study results of PIXUVRI at AACR-NCI-EORTC meeting

Study: Skin tanning gene linked to higher risk for testicular cancer in white men

New prognostic tool forecasts survival of patients with advanced prostate cancer

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

Combination of heat, doxorubicin drug and nanotech system may improve ovarian cancer treatment

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

Researchers find novel drug target for anaplastic thyroid carcinomas

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Light pulses stimulate designer peptides to trigger death pathway in cancerous cells

New $1.9M research grant to support investigators to detect tumors in earliest stages of formation

Acacia Pharma reports positive results from APD515 Phase II study for treatment of xerostomia

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Promising new type of cancer treatment to benefit more patients

Results announced for Phase II PRECEDENT trial of vintafolide for treatment of platinum-resistant ovarian cancer

NICE issues second draft guidance on PIXUVRI for treatment of aggressive B-cell NHL

Football-shaped artificial particles teach immune cells to recognize, destroy cancer cells

PARP inhibitor drugs and chemotherapy can help women with ovarian cancer live longer

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in